• Letters

    Thoughts From Your Colleagues

    Download PDF

    Working With Industry During COVID

    As the COVID-19 pandemic evolved last spring, mask wear­ing became ubiquitous in ophthalmology practices across the country and around the world. One problem with patients wearing masks is that, depending on the fit of the mask, a stream of warm, moist exhaled air can escape between the patient’s skin and the mask. This causes condensation or fogging on the diagnostic lens, which disrupts the examiner’s view to the optic nerve, macula, and other structures.

    Bradley A. Sacher, MD, a colleague at the Wheaton Eye Clinic, and I recognized this problem and began to apply a variety of technical solutions to try to avoid the fogging problem. Eventually we settled on a barrier design for a device that attaches to the diagnostic lens. We undertook the challenge of design with the help of a 3-D printer, and we created our first prototypes.

    We were then connected with the team at Volk, which has taken our invention and made it into a real product. Our hope is that ophthalmologists around the world will find these fog shields (named the ClearPod) useful in their clinics, making a difficult situation, with new protocols and proce­dures, just a little bit easier.

    To conclude, let me recommend to all ophthalmologists that we can be innovators, striving to find solutions to the problems encountered every day in the clinic and in surgery, knowing that talented engineers and designers are ready to take raw or prototyped ideas and make them into real solu­tions that we can all use. Innovators should be encouraged.

    Jeremy B. Wingard, MD
    Wheaton Eye Clinic, Wheaton, Ill.

    Relevant financial disclosures: Volk: P.

    For full disclosures and the disclosure key, see below.

    Full Financial Disclosures

    Dr. Wingard Aerie: C; Allergan: C,L; Volk: P.

    Disclosure Category

    Code

    Description

    Consultant/Advisor C Consultant fee, paid advisory boards, or fees for attending a meeting.
    Employee E Employed by a commercial company.
    Speakers bureau L Lecture fees or honoraria, travel fees or reimbursements when speaking at the invitation of a commercial company.
    Equity owner O Equity ownership/stock options in publicly or privately traded firms, excluding mutual funds.
    Patents/Royalty P Patents and/or royalties for intellectual property.
    Grant support S Grant support or other financial support to the investigator from all sources, including research support from government agencies (e.g., NIH), foundations, device manufacturers, and/or pharmaceutical companies.

    ___________________________

    Editors’ note: If you’re interested in innovation, attend the next Eyecelerator event. Learn more at eyecelerator.com.

    An Additional Perspective on Giant Cell Arteritis

    I read with interest “GCA, Part 2: Malpractice Lessons and Case Studies” (Clinical Update, December 2020), which offers malpractice lessons from the Ophthalmic Mutual Insurance Company and three case studies to consider. I’m writing to add another perspective on the issue.

    Diagnostic prediction models can aid in the objective risk stratification for giant cell arteritis (GCA). An online risk calculator for GCA that considers headache, scalp tenderness, jaw claudication, vision loss, diplopia, and gender while maintaining age and bloodwork values as continuous vari­ables is available at https://goo.gl/THCnuU.

    In a study of 1,201 consecutive patients who underwent temporal artery biopsy, the best predictors for GCA were age, jaw claudication, vision loss, and the platelet level.1 Platelets are also an acute phase reactant, and the platelet level was a more reliable predictor of GCA than were the erythrocyte sedimentation rate or C-reactive protein. Patients with a positive temporal artery biopsy had an average platelet level of 372 × 109/L (±143), and those with a negative temporal artery biopsy had an average platelet level of 283 × 109/L (±105; p < 0.001).

    Edsel B. Ing, MD, PhD, FRCSC, MPH
    Michael Garron Hospital, University of Toronto

    ___________________________

    1 Ing EB. Clin Ophthalmol. 2019;13:421-430.

    Make 2021 Your Year of Advocacy

    About a year ago, a friend sent me a photo of a young anes­thesia provider in another state. Donning a surgical mask, with a nasal cannula pumping oxygen to him underneath, he had taped a plastic bag over his head as makeshift PPE to intubate a COVID-19 patient. This stark image stirred me into action. I wrote my first advocacy letter to Gov. Tim Walz and the Minnesota congressional delegates with others in my state society. The letter helped open the governor’s eyes to the PPE shortage and spurred him to enact an executive stay-at-home order.  

     As health care providers, we have the unique opportu­nity to be the voice for those who are not at the table. The murder of George Floyd and the subsequent use of blinding force by police against protesters clarified for me how we, as ophthalmologists, need to step outside of our clinics and into advocacy to prevent vision loss.

    These experiences made me realize that advocating for legislation in support of patients and providers effects systemic change in the larger community. For example, the scope of practice battles that are ongoing across the United States have a direct link to patient safety.

     I invite you to get involved. Join me on April 23 and 24 for the Mid-Year Forum and on May 5 for the Congressional Advocacy Day. Both virtual, free events provide the opportu­nity to make your and your patients’ voices heard.

    Sasha Strul, MD, FAAP
    Young Ophthalmologist Section Chair,
    Minnesota Academy of Ophthalmology, Minneapolis

    ___________________________

    Editors’ note: You can register for the 2021 Mid-Year Forum at aao.org/myf and for Congressional Advocacy Day at aao.org/cad.